Clinical trials
HER2-positive Breast Cancer clinical trials
Below are recruiting her2-positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 242 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04886531RecruitingPhase 2
Pre-surgery neratinib plus hormone therapy with trastuzumab
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
Chicago, IllinoisAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT04899908RecruitingPhase 2
Brain radiation with or without gadolinium nanoparticles for brain metastases
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
Boston, MassachusettsAges 18 years+ - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+ - NCT06970912RecruitingPhase 2
ctDNA-Guided Reduced Chemo in HR+/HER2- Breast Cancer
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT07600164RecruitingPhase 4
Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04993014RecruitingPhase 2
De-escalating treatment after HER2-positive breast cancer responds
This study looks at whether some people with HER2-positive breast cancer can safely receive less (de-escalated) treatment after they finish chemotherapy plus HER2-targeted drugs before surgery. It specifically focuses on people whose cancer shows a complete response on the surgery pathology report.
São PauloAges 18 years+ - NCT05020860RecruitingPhase 2
Study how early breast cancer responds on imaging and under a microscope
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Houston, TexasAges 18 years+ - NCT05035836RecruitingPhase 2
Test drug after early HER2-positive breast cancer surgery
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
Houston, TexasAges 18 years+ - NCT05115474RecruitingPhase 2
Screening brain MRI study for stage IV breast cancer
This trial checks whether taking screening brain MRI scans in people with stage IV breast cancer helps find brain involvement earlier. It may help guide treatment decisions for those who would otherwise only get brain imaging after symptoms start.
Clearwater, FloridaAges 18 years+ - NCT05325632RecruitingPhase 2
HER2 breast cancer vaccine plus chemo and targeted antibodies
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Tampa, FloridaAges 18 years+ - NCT05388149RecruitingPhase 2
Neratinib plus Kadcyla to treat leftover HER2 breast cancer
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
Toronto, OntarioAges 18 years+ - NCT05406635Recruiting
Imaging vs blood tests to guide heart-safe HER2 treatment
This trial compares whether special heart imaging or blood tests better helps monitor heart safety while you receive HER2-targeted therapy (like trastuzumab, with or without pertuzumab) plus chemotherapy. It may help doctors catch early heart stress and choose the safest treatment plan for you.
AalborgAges 18–90 - NCT05420454RecruitingPhase 4
Neoadjuvant treatment for breast cancer before surgery
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
Hangzhou, ZhejiangAges 18 years+ - NCT05420467RecruitingPhase 4
Trial of add-on breast cancer treatment after surgery
This Phase 4 study tests an additional (adjuvant) treatment for breast cancer after surgery and standard follow-up care. It may help lower the chance the cancer comes back, but you must match specific tumor and body-chemistry requirements to join.
Hangzhou, ZhejiangAges 18 years+ - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT05582499RecruitingPhase 2
Neoadjuvant treatment study for certain breast cancers
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05638594RecruitingPhase 2
Neoadjuvant drug study for hormone- and HER2-positive breast cancer
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
Shenyang, LiaoningAges 18–75 - NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70 - NCT05769010RecruitingPhase 2
HER2-positive or low breast cancer brain metastasis drug study
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Zhengzhou, HenanAges 18–75 - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT05800275RecruitingPhase 2
Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
BordeauxAges 18 years+ - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-positive breast cancer?
- Yes. Clin2 currently lists 242 recruiting her2-positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HER2-positive Metastatic Breast Cancer
- HER2-positive Advanced Breast Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- HER2-positive Early Breast Cancer
- HR Positive/HER2 Low Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.